Pharmaceutical Industry

Samsung Bioepis emerging as strong player in the Autoimmune space

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Samsung Bioepis’ and Biogen’s Imraldi as a treatment for all indications of the reference product, AbbVie’s Humira (adalimumab). With 2016 global sales of approximately $16.1 billion, Humira will face competition from Imraldi, which will offer the second adalimumab biosimilar to patients …

Samsung Bioepis emerging as strong player in the Autoimmune space Read More »

Zika virus cure still a discovery priority

Last summer, the Zika virus outbreak triggered a worldwide health alert. Today, pathogen is a discovery priority as there is still no treatment to combat the disease Even though the initial hysteria has quietened, the Zika virus is still impacting the public. With reports of babies being born in Brazil’s favelas with microcephaly and sightings …

Zika virus cure still a discovery priority Read More »

Automating Unpredictable Processes The key to the pharmaceutical industry’s R&D efficiency By Chuck Piccirillo, CEO and Founder, Zealic Solutions

While the $2.6 billion cost of bringing a new drug to market as found in a recent Tufts Center for the Study of Drug Development (CSDD) research report is jaw-dropping, of greater concern is the fact that this figure has increased 145% since the last time the study was conducted in 2003. Despite a significant …

Automating Unpredictable Processes The key to the pharmaceutical industry’s R&D efficiency By Chuck Piccirillo, CEO and Founder, Zealic Solutions Read More »